SOX10 suppression contributes to BRAF- and/or MEK-inhibitor resistance in BRAF mutated melanoma, by activating TGFβ signalling to upregulate EGFR and PDGFRB [57], whilst increasing SOX9 transcript abundance has been observed in breast cancer EMT [58]. This evidence concerns the gene PDGFRB and breast carcinoma.